The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.25 - 1 µg/ml.
This antibody (using 100µl/well antibody solution) can be used as the detection antibody along with ab9675 as the capture antibody to detect at least 0.2 - 0.4 ng/well of recombinant Human MIP-1β.
Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 10 kDa.
The detection limit for recombinant Human MIP-1β is 1.5 - 3.0 ng/lane under either reducing or non-reducing conditions.
Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B.
Belongs to the intercrine beta (chemokine CC) family.
N-terminal processed form MIP-1-beta(3-69) is produced by proteolytic cleavage after secretion from peripheral blood lymphocytes.